Point72 Asset Management L.P. Invests $3.44 Million in Replimune Group, Inc. (NASDAQ:REPL)

Point72 Asset Management L.P. bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 283,966 shares of the company's stock, valued at approximately $3,439,000. Point72 Asset Management L.P. owned approximately 0.42% of Replimune Group as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Sterling Capital Management LLC boosted its position in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after acquiring an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after acquiring an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its position in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after acquiring an additional 8,183 shares during the last quarter. Quantinno Capital Management LP bought a new stake in shares of Replimune Group during the 4th quarter valued at about $127,000. Finally, XTX Topco Ltd bought a new stake in shares of Replimune Group during the 4th quarter valued at about $137,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $19.43.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,952 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the transaction, the insider now directly owns 146,933 shares of the company's stock, valued at approximately $1,184,279.98. The trade was a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Philip Astley-Sparke sold 32,279 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $260,168.74. Following the transaction, the director now directly owns 1,405,071 shares in the company, valued at $11,324,872.26. This trade represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock valued at $603,655 in the last ninety days. Company insiders own 8.80% of the company's stock.

Replimune Group Trading Down 4.7%

Replimune Group stock traded down $0.41 during trading hours on Friday, reaching $8.35. The company had a trading volume of 1,461,131 shares, compared to its average volume of 926,127. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The company has a 50-day moving average price of $8.63 and a 200 day moving average price of $11.21. The firm has a market cap of $643.08 million, a price-to-earnings ratio of -2.72 and a beta of 0.68. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the firm earned ($0.25) earnings per share. Equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.